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Abstract: The CYP17A1 gene regulates sex steroid biosynthesis in humans through 17α-hydroxylase/
17,20 lyase activities and is a target of anti-prostate cancer drug abiraterone. In a 46, XY patient
with female external genitalia, together with a loss of function mutation S441P, we identified a novel
missense mutation V366M at the catalytic center of CYP17A1 which preferentially impaired 17,20 lyase
activity. Kinetic experiments with bacterially expressed proteins revealed that V366M mutant enzyme
can bind and metabolize pregnenolone to 17OH-pregnenolone, but 17OH-pregnenolone binding
and conversion to dehydroepiandrosterone (DHEA) was impaired, explaining the patient’s steroid
profile. Abiraterone could not bind and inhibit the 17α-hydroxylase activity of the CYP17A1-V366M
mutant. Molecular dynamics (MD) simulations showed that V366M creates a “one-way valve”
and suggests a mechanism for dual activities of human CYP17A1 where, after the conversion of
pregnenolone to 17OH-pregnenolone, the product exits the active site and re-enters for conversion to
dehydroepiandrosterone. The V366M mutant also explained the effectiveness of the anti-prostate
cancer drug abiraterone as a potent inhibitor of CYP17A1 by binding tightly at the active site in the
WT enzyme. The V366M is the first human mutation to be described at the active site of CYP17A1
that causes isolated 17,20 lyase deficiency. Knowledge about the specificity of CYP17A1 activities is
of importance for the development of treatments for polycystic ovary syndrome and inhibitors for
prostate cancer therapy.
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1. Introduction
The Cytochrome P450 proteins that are located in the endoplasmic reticulum are responsible for
the metabolism of xenobiotics, drugs and steroid hormones (Figure 1) and are part of the microsomal
mixed oxidase system [1–3]. Cytochrome P450c17 (CYP17A1) is required for the biosynthesis of steroid
hormones in all vertebrates. The CYP17A1 is the qualitative regulator of the biosynthesis of sex
steroid in humans (Figure 2) [4]. CYP17A1 catalyses multiple reactions in the steroid pathway [5–7];
chiefly among them, its 17α-hydroxylase activity is essential for the production of 17OH-pregnenolone
(17OH-PREG) and 17OH-progesterone (17OH-PROG) which are precursors of cortisol, and its 17,20
lyase activity is required for the generation of the precursor of sex steroids, dehydroepiandrosterone
(DHEA) (Figure 2). These two activities of the CYP17A1 determine the type of steroid hormone
synthesized in different cells and tissues; if the CYP17A1 is absent, mineralocorticoids are produced,
if only the 17α-hydroxylase activity of the CYP17A1 is present, glucocorticoids are made; and if both the
17α-hydroxylase and the 17,20 lyase activities of the CYP17A1 are present, sex steroid precursors are
generated [4]. Overproduction of androgens by the specific activation of CYP17A1-17,20 lyase activity
has been implicated in the pathogenesis of the polycystic ovary syndrome [4]. CYP17A1 is a target
for prostate cancer therapy by inhibitor abiraterone (Zytiga by Johnson & Johnson, New Brunswick,
USA) [8–12].
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Figure 1. Schematic diagram of CYP17A1 and P450 oxidoreductase (POR) interaction in the 
membranes. The nicotinamide adenine dinucleotide phosphate (NADPH) molecules bind to POR, 
which is embedded into the membranes of endoplasmic reticulum and donate a pair of electrons, one 
at a time, which are received by the FAD. Transfer of electrons to FAD creates a change in 
conformation of POR, allowing the FAD and FMN groups to move towards each other, which 
facilitates the transfer of electrons from FAD to FMN. The FMN domain of POR interacts with the 
CYP17A1 and transfers electrons for catalytic activities. 
Similar to other microsomal P450 proteins, CYP17A1 also requires electrons supplied from 
reduced nicotinamide adenine dinucleotide phosphate (NADPH) through cytochrome P450 
oxidoreductase (POR) (Figure 1) [2,13–16]. The 17,20 lyase activity of CYP17A1 is influenced by the 
presence of cytochrome b5 (CYB5A) in specific locations in different cells and tissues and guides the 
steroid hormone pathway in different directions [4] (Figure 2). 
Figure 1. Schematic diagram of CYP17A1 and P450 oxidoreductase (POR) interaction in the membranes.
The nicotinamide adenine dinucleotide phosphate (NADPH) molecules bind to POR, which is
embedded into the membranes of endoplasmic reticulum and donate a pair of electrons, one at a
time, which are received by the FAD. Transfer of electrons to FAD creates a change in conformation of
POR, allowing the FAD and FMN groups to move towards each other, which facilitates the transfer
of electrons from FAD to FMN. The FMN domain of POR interacts with the CYP17A1 and transfers
electrons for catalytic activities.
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convert 17α-hydroxyprogesterone (17OH-PROG) to androstenedione. The DHEA is the precursor for 
androgen production and (dihydrotestosterone) DHT is the potent form of androgen with higher 
affinity towards androgen receptor (AR) than testosterone (T). The 17α-hydroxy position of 17OH-
PREG is highlighted in red to show the difference from PREG. 
Along with CYB5A, higher molecular ratios of POR and phosphorylation of CYP17A1 also 
influence 17,20 lyase activity [17–21]. Recently several X-ray crystal structures of solubilized human 
CYP17A1 have been reported, but the structural basis of 17α-hydroxylase and 17,20, lyase activities 
remains unknown [22–26]. Generally, the mutations that affect the steroid-binding domain of 
CYP17A1 or disturb the interaction with P450 oxidoreductase (POR) for electron transfer, cause 
combined 17α-hydroxylase and 17,20 lyase deficiency, and are those more frequently found in 
humans [4,25]. Very few point mutations in CYP17A1 (R347C/H, R358Q) have been reported to cause 
Figure 2. Steroid biosynthetic ath ay. In humans, 17,20 lyase activity of CYP17A1 converts
17α-hydroxypregnenolone (17OH-PREG) to dehydroepiandrosterone (DHEA) but does not effectively
convert 17α-hydroxyprogesterone (17OH-PROG) to androstenedione. The DHEA is the precursor for
androgen production and (dihydrotestosterone) DHT is the potent form of androgen with higher affinity
towards androgen receptor (AR) than testosterone (T). The 17α-hydroxy position of 17OH-PREG is
highlighted in red to show the difference from PREG.
Similar to other microsomal P450 protei s, CYP17A1 also requires electrons supplied from reduced
nicotinamide adenine dinucleotide phosphate (NADPH) through cytochrome P450 oxidoreductase
(POR) (Figure 1) [2,13–16]. The 17,20 lyase activity of CYP17A1 is influenced by the presence of
cytochrome b5 (CYB5A) in specific locations in different cells and tissues and guides the steroid
hormone pathway in different directions [4] (Figure 2).
Along with CYB5A, higher molecular ratios of POR and phosphorylation of CYP17A1 also
influence 17,20 lyase activity [17–21]. Recently several X-ray crystal structures of solubilized human
CYP17A1 have been reported, but the structural basis of 17α-hydroxylase and 17,20, lyase activities
remains unknown [22–26]. Generally, the mutations that affect the steroid-binding domain of CYP17A1
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or disturb the interaction with P450 oxidoreductase (POR) for electron transfer, cause combined
17α-hydroxylase and 17,20 lyase deficiency, and are those more frequently found in humans [4,25].
Very few point mutations in CYP17A1 (R347C/H, R358Q) have been reported to cause isolated 17,20
lyase deficiency [27–30] (Table 1). These mutations are thought to interfere with CYB5A binding
and/or electron transfer from POR to CYP17A1 during the 17,20 lyase reaction.
Table 1. Reported cases of CYP17A1 mutations causing isolated 17,20 lyase deficiency [27–30].
The mutation E305G which was initially reported by Sherbet et al. [28] to cause isolated 17,20 lyase
deficiency, was later reported by Tiosano et al. [30] to also result in combined 17α-hydroxylase/17,20
lyase deficiency, similar to other common mutations in CYP17A1 [30].
17OH
Steroids
Basal
17OH
Steroids
Stimulated
Cortisol
Basal
Cortisol
Stimulated Activities (% of WT) Ref
17OHase 17,20 lyase
Normal Hyperresponsive Normal Areactive 65 5 Geller 1997 [27]
Elevated Hyperresponsive Normal Areactive 65 5 Geller 1997 [27]
Slightly
elevated Not reactive Low normal Areactive
van den Akker
2002 [29]
Normal Normal Low normal Areactive van den Akker2002 [29]
Normal/Elevated Reactive Low normal Hyporeactive 60 0 van den Akker2002 [29]
Normal/Elevated Reactive Low normal Hyporeactive 60 0 van den Akker2002 [29]
Normal/Elevated Reactive Low Hyporeactive 100 0 Sherbet 2003 [28]
Normal/Elevated Normal Low normal Hyporeactive Tiosano 2008 [30]
Normal/Elevated Normal Low normal Hyporeactive Tiosano 2008 [30]
Normal/Elevated Normal Low normal Hyporeactive Tiosano 2008 [30]
Normal/Elevated Normal Low normal Hyporeactive Tiosano 2008 [30]
Normal/Elevated Normal Low normal Hyporeactive Tiosano 2008 [30]
Normal/Elevated Normal Low normal Hyporeactive Tiosano 2008 [30]
Normal/low Hyporeactive Low normal Areactive 43 0/0 This report
Lack of 17α-hydroxylase activity of CYP17A1 results in a compensatory overproduction of
corticosterone and deoxycorticosterone with a weak glucocorticoid and significant mineralocorticoid
action, which results in severe hypertension and hypokalemia. On the other hand, the 17,20 lyase
deficiency results in a lack of sex steroids, leading to the 46, XY disorder of sexual development
(DSD) with severe undervirilization in the “male” newborn, and deficient pubertal development and
fertility in both sexes [4]. Previously, we have reported that disturbing the interaction of CYP17A1
with P450 oxidoreductase (POR) for electron transfer causes combined 17α-hydroxylase and 17,20
lyase deficiency [2,14,16,31–34]. Mutations identified on the surface of CYP17A1 (R347C/H, R358Q)
have been proposed to diminish the interaction with POR but could not explain the mechanism of
their specific effect on 17,20 lyase activity [27,35].
Recently we have shown that in the earliest reported cases of apparent isolated 17,20 lyase
deficiency, that were based solely on hormonal and morphological findings and without genetic
analysis, the CYP17A1 and POR genes were actually normal and mutations in AKR1C2 and AKR1C4
were found to cause a similar phenotype [36–38]. In the current report, we are describing a novel active
site mutation in CYP17A1 that specifically abolishes the 17,20 lyase activity.
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2. Results
2.1. Case Report and Genetic Analysis of the Patient
The patient was born at term, with normal female external genitalia, after a normal spontaneous
pregnancy, whereas an older sister was the product of an insemination with donor semen to avoid
retinitis pigmentosa carried by the father’s family. At 2 months of age, the patient was operated
for a right inguinal hernia. No female internal sex organs were found and karyotype was 46,
XY. During the procedure, a gonad was detected and biopsied showing to be a testis (Figure 3).
Electrolytes were normal and baseline hormone values at 3 months of age revealed moderately elevated
ACTH, highly elevated PROG, normal/low 17OH-PREG, 17OH-PROG, 11-deoxycortisol and cortisol,
undetectable androstenedione (∆4A) and normal DHEA-S and Testosterone for female sex (Table 2).
At the age of 5 months a human chorionic gonadotropin (hCG) test (500 IU/d × 3) was performed
which showed no increase of ∆4A and T upon stimulation (Table 2). At 20 months of age an ACTH
test (Synacthen®) revealed a moderately elevated baseline ACTH and a normal baseline plasma renin
activity (PRA), Prog was highly elevated and further increased upon stimulation, whereas baseline
17OH-PREG, 17OH-PROG, cortisol, 11-deoxycortisol, and aldosterone were normal/low, and did
not increase after stimulation (Table 2). Baseline DHEA-S and baseline and stimulated ∆4A were
undetectable. Because of female phenotype and obvious biochemical lack of androgens, female sex of
rearing was confirmed and a gonadectomy was performed at the age of 20 months. Testes morphology
showed abnormal findings similar to those found in androgen-insensitive patients (Figure 4a). Blood
pressure (BP) control was recommended as a precautionary measure while hydrocortisone replacement
therapy was postponed depending on follow-up. BP controls revealed normal values. Baseline BP
controls revealed normal values up to 11 years of age as well a 24-h ambulatory BP monitoring
performed at 8 years of age (baseline and at the end of 3 months of therapy with hydrocortisone:
6 mg/m2 in 3 daily doses).
Initial genetic analysis of the genes for AR and SRD5A2 were normal [39,40] and hormonal findings
suggested partial 17α-hydroxylase and complete 17,20 lyase deficiencies (Table 2). The CYP17A1 gene
was analyzed and compound heterozygous point mutations c.1096G > A (V366M) and c.1321T > C
(S441P) in exons 6 and 8 were identified (Figure 4b). The healthy fertile mother was found to carry the
V366M mutation, a residue which is highly conserved across species (Figure 4c), while the father was
normal. Therefore, CYP17A1 S441P might be a de novo mutation in the patient although paternity
testing was not performed. The mutations in the patient are likely to be on different alleles as even
total disruption of one copy of CYP17A1 does not result in disease. As both CYP17A1 mutations
have not been described previously, and as our patient presented with a very rare phenotype of
apparent isolated 17,20 lyase deficiency, we performed further investigations to characterize these
novel mutations.
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Figure 3. Genetic characterization and testis histology of the 46, XY disorder of sexual development
(DSD) patient with a female phenotype. (a) Histopathologic studies revealed that both gonads consisted
of atrophic and immature seminiferous tubules which were filled almost exclusively with pre-Sertoli
cells. The fertility index was 5% with abortive and fetal type spermatogonia (i–iv); iii. in some areas,
the tubules formed lobule-like structures similar to pseudo-hamartomas surrounded by collagen
fibrous tissue; iv. nests of fibroblastic pre-Leydig cells were found in the interstitium. Albuginea and
epidydimus were unremarkable. H/E-hematoxylin-eosin stain. (b) Family tree and electropherograms
showing the index patient, the parents and the half-sister. Both, the patient and mother harbored
the heterozygot 096G > A (p.Val366Met) mutation in exon 6, while the heterozygote c.1321T > C
(p.Ser441Pro) mutation in exon 8 was only pres nt in the patient. Th father and the half-sister were
both non-carriers of either mutation. (c) Alignment of human CYP17A1 amino acid sequence with a
range of CYP17A1 proteins from other species found in the Universal Protein Knowledgebase (UniProt)
database. The Valine 366 residue is highly conserved in all species studied.
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Table 2. Laboratory findings in our patient harboring compound heterozygote CYP17A1 mutations.
Age 3 Months 5 Months 20 Months 5 Years 6.5 Years
Parameter Unit Basal NormalRange
hCG Test (500
IU/d × 3)
Normal
Range Basal
Normal
Range ACTH-Stimulated Basal Basal
Normal
Range
Sodium mEq/L 140 136–145 - 141 136–145 - 144 136–145
Potassium mEq/L 4.0 3.5–5.1 - 4.6 3.5–5.1 - 4.7 3.5–5.1
ACTH pg/mL 81 9–50 82 9–50 66 9–50 - 62 46 9–50
Progesterone ng/dL 222 5–80 - 251 10–50 425 522 339 10–50
17OH Preg ng/dL 132 60–830 27 60–830 13 10–50 - - -
17OHProg ng/dL 300 40–460 40 40–460 29 19–159 35 110 80 10–470
DHEA-S µg/dL <5 5–62 <5 5–62 <5 5–190 - <5 <5 5–95
11-Deoxycortisol ng/dL 1100 1450 ± 790 200 1450 ± 790 140 186 ± 116 - 87 - 205 ± 108
Cortisol µg/dL 3.7 4.3–22.2 8.6 4.3–22.2 8.9 4.3–22.2 7.8 7.1 4.1 4.3–22.4
∆4A ng/dL <30 63 ± 39 <3 63 ± 39 <30 30–330 <30 - <30 30–330
Testosterone ng/dL 7 140 ± 132 <4 140 ± 132 28 15–30 16 - -
LH IU/L - - 0.3 0.2–1.0 - <0.07 - 0.2–1.0
FSH IU/L - - 9 0.4–2.0 - 4.3 - 0.4–2.0
PRA ng/mL/h - - 1.8 0.6–21.3 - - 0.1 0.3–6.4
Aldosterone ng/dL - - 12.1 14–114 11.5 6.2 9–66
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Figure 4. rine steroid profile of the patient, heterozygote mother, father, and sister.
The steroid analysis was performed on 24 h urine samples by GC/MS. Note the lack
of androgens (ETIO, ANDRO) and the relative increase in corticosterone metabolites
(THA, THB, 5α-THB) in the steroid profile of the patient compared to mother and father.
THA—tetrahydro-11-dehydrocorticosterone; THB—tetrahydro corticosterone; 5a-THB-5α-tetrahydro
corticosterone; THE—tetrahydrocortisone; THF—tetrahydrocortisol; 5a-THF-5α-tetrahydrocortisol;
ETIO—etiocholanolone; ANDRO—androsterone; SS (ISTD)—internal standard.
2.2. Steroid Analysis
Urine steroid profiling of the patient revealed almost complete loss of androgen metabolites,
low-normal cortisol and elevated corticosterone metabolites (Figure 5), suggesting partial
17α-hydroxylase and complete 17,20 lyase deficiency. All other family members had normal steroid
profiles (Figure 4).
2.3. Loss of 17,20 Lyase Activity of CYP17A1 by the V366M Mutation
To investigate the molecular basis of these mutations we produced both mutant and the wild-type
CYP17A1 proteins and performed enzyme kinetic assays (Table 3).
Comparison of mutant and wild-type proteins revealed that both mutations V366M and S441P
affected CYP17A1 enzyme activities and therefore qualified as disease-causing mutations. The S441P
mutation was found to cause a complete loss of both 17α-hydroxylase and 17,20 lyase activities of
CYP17A1. Structural analysis of the S441P mutation indicated that heme binding may be affected
(Figure 5), and quantification of heme in the S441P mutant revealed that it contained less than 5% of
heme compared to the wild-type enzyme (Table 4).
The CYP17A1-V366M protein retained >40% of WT activity in the 17α-hydroxylase assay but
had no activity in the 17,20 lyase assay using 17OH-PREG as substrate (Table 3). Therefore, S441P is
a loss-of-function CYP17A1 mutation whereas V366M qualifies as a rare mutation predominantly
affecting CYP17A1-17,20 lyase activity in vitro. Therefore, the S441P mutation effectively created
a non-functional allele and allowed us to explore the specific effects of the V366M mutation in
greater detail.
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CYB5A 1.0 
Figure 5. Location of S441P mutation in CYP17A1 structure showing the affected amino acids.
The cysteine 442 is shown in yellow, serine 441 is in magenta and arginine 440 is in cyan. Both the
cysteine 442 and arginine 440 are required for heme binding and the serine 441 to proline mutation
creates a bend in the loop containing the cysteine 442 and arginine 440 residues, resulting in loss of
heme binding that leads to an inactive enzyme.
Table 3. Kinetic parameters for the metabolism of PROG to 17OH-PROG (17hydroxylation) and
17OH-PREG to DHEA (17,20 lyase reaction) by WT and V366M mutant of CYP17A1.
CYP17A1 Variant 17α-HydroxylasePROG to 17OH-PROG
17,20 Lyase17
OH-PREG to DHEA
Km (µM) Vmax (min−1) Cat Eff (%) Km (µM) Vmax (min−1)
WT 6.1 ± 0.7 0.71 100 0.92 ± 0.07 0.025 ± 0.004
V366M 8.4 ± 0.9 0.42 43 - -
S441P - - - - -
Table 4. Heme content of proteins used in assays.
Protein Preparation Heme Content (nnol/nmol of Protein)
CYP17A1 WT 0.93
CYP17A1_V366M 0.95
CYP17A1-S441P <0.05
CYB5A 1.0
2.4. The 17OH-PREG is Not an Effective Inhibitor of 17α-Hydroxylase Reaction by the V366M Mutant
For the human CYP17A1, PREG, 17OH-PREG, and PROG re all very good substrates and,
therefore, are expected to compete for the binding to CYP17A1 when more than one substrate is present
at the same time. To test if there is a difference between the WT versus the V366M mutant of CYP17A1,
we used 17OH-PREG as an inhibitor for the 17α-hydroxylase reaction of CYP17A1 using radiolabeled
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[3H]PROG as substrate. For the WT CYP17A1, 17OH-PREG inhibited the 17α-hydroxylation of PROG
with an observed IC50 value of 1.7 µM (Table 5).
Table 5. Binding and inhibition studies of WT and the V366M mutant of CYP17A1.
CYP17A1_WT CYP17A1_V366M
Binding studies Kd (nM) Kd (nM)
Binding of PROG 163 ± 29 287 ± 35
Binding of PREG 62 ± 17 92 ± 15
Binding of 17OH-PREG 142 ± 38 -
Binding of Abiraterone 85 ± 23 -
Inhibition studies IC50 (µM) IC50 (µM)
Inhibition of PROG
17α-hydroxylation by Abiraterone 0.04 ± 0.01 -
Inhibition of PROG
17α-hydroxylation by 17OH-PREG 1.7 ± 0.2 -
Inhibition of PROG
17α-hydroxylation by PREG 0.9 ± 0.15 1.4 ± 0.2
For the V366M mutant of CYP17A1, no inhibition of the 17α-hydroxylation of PROG was observed
by 17OH-PREG within the range of concentration used in the assay (0–100 µM). These results indicated
difficulty in the binding of 17OH-PREG to the V366M mutant of CYP17A1. By contrast, when PREG
was used as an inhibitor in the 17α-hydroxylation reaction catalyzed by CYP17A1 using PROG as a
substrate, both the WT as well as V366M mutant enzymes were inhibited with apparent IC50 values
of 0.9 µM for the WT enzyme versus 1.4 µM for the V366M mutant (Table 5). This suggests that both
PREG and PROG can bind and be metabolized by the V366M variant of CYP17A1 but 17OH-PREG
could not be used as a substrate by the mutant enzyme.
2.5. Computational Structural Analysis by Molecular Dynamics
We used the recently solved crystal structures of the human CYP17A1 [22,23] to make in-silico
mutations and analyzed the changes through molecular dynamics (MD) simulations. In the CYP17A1
crystal structure, the active site for the binding of steroids is characterized by the positioning of residues
V366, N202 and E305 (Figure 6). This led us to hypothesize that the specific space requirements exist
for correct positioning of 17α-hydroxysteroids. The larger side chain of methionine in the V366M
mutant protruded into the active site of CYP17A1 (Figure 7). Interestingly the shape of the protruding
side chain of methionine 366 indicated that it might restrict the movement of steroids only in one
direction, allowing the 17-hydroxy-steroids to leave the active site by the flexibility of movement in
one direction, but creating a strong steric hindrance in the path of incoming steroids.
One of the most intriguing questions about CYP17A1 activities has been whether the
17α-hydroxysteroid can stay in the catalytic site and be metabolized again to androgen precursors,
or whether the product of 17α-hydroxylase reaction leaves the active site and re-enters for the second
reaction (Figure 7a). The one-way valve created by V366M mutation provides some answers to this
question for the human CYP17A1. The presence of 17α-hydroxylase activity in the V366M variant
suggested that PREG can get into the active site and be converted to 17OH-PREG (Figure 7b). If the
17OH-PREG was not able to leave the active site, it would have created an irreversible inhibition and the
enzyme would have been unable to carry out further reactions. However, the 17α-hydroxylase reaction
progressed (Figure 4 and Table 3), indicating that 17OH-PREG can exit the active site. Furthermore,
if the 17OH-PREG could be converted without exiting the active site, then DHEA formation should
have been observed as in case of the wild-type enzyme.
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mutations may interfere with binding of POR and /or cytochrome b5. The E305 residue at the active
site is important for orientation of the substrate and its mutation has been shown to alter substrate
specificity and lead to a preference for progesterone as the more efficient substrate. The V366 is located
exactly at the active site of the CYP17A1.
However, DHEA was absent in both the in vitro enzyme reactions of the V366M mutant of
CYP17A1 (Table 3) as well as in the urine of the patient (Figure 4), clearly indicating that 17OH-PREG
must exit the active site after the 17α-hydroxylase reaction. If the problem was with the exit of DHEA,
then that would also have created an irreversible inhibition by blocking the active site with one
molecule of DHEA per unit of enzyme and further enzymatic activity would have come to a halt,
but that was cle rly not the case from the in vitro enzyme analysis as well as the patient’s uri e st oid
pr file (Figure 4 and Table 3). In the case of bovine CYP17A1, about 20% of pregne olone consumed
in the reaction could be converted to DHEA without exiting the active site [41]. When PROG was
used as a substrate, compared to 17OH-PREG the dissociation of 17OH-PROG was 10 times faster.
The release of the intermediate reaction was much faster than 17,20 lyase reaction and that prevented
the direct formation of androstenedione from PROG. There are significant differences in activities of
CYP17A1 between different species and the human enzyme has a very poor affinity for 17OH-PROG
as substrate [25,42,43].
To further study this mechanism, we employed molecular dynamics simulations for the analysis
of steroid binding in the active site of wild-type and the V366M mutant of CYP17A1. This was
confirmed by the ensemble docking experiments which (for wild-type protein) yielded ligand poses
in close proximity to the hem and highly resembling the co-crystallized abiraterone in the CYP17A1
(PDB: 3RUK) structure [22]. The validity of ou docking protocol was supported by a set of additional
CYP17A1 crystal structures containing all the ligands of interest (PDB codes: 4NKW, 4NKX, 4NKY,
and 4NKZ) in very similar poses enabling hydrogen-bonding to a distal N202 residue for PROG/PREG
but not for 17OH-PREG [23]. Based on these observations, we hypothesized that the methionine
side-chain could prevent a closer proximity to the heme iron necessary for the substrates undergoing
lyase reaction [23,24]. To check this, we performed an additional pair of simulations with 17OH-PREG
docked into the wild-type and mutant binding sites. Thus, we could indeed measure that the average
distance between the ligand C17 atom and the heme iron differed in these systems (4.4 Å for wild-type
and 6.3 Å for V366M mutant) (Figure 8c,d). While these results cannot be compared directly to the
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crystal structure of CYP17A1 with 17OH-PREG (PDB code 4NKZ; the O17-Fe distance between 3.4
and 3.9 Å depending on the chain), this hypothesis is well in line with all our experimental data and
recently reported structures of human CYP17A1 in complexes with steroid substrates. In addition,
the simulations, as well as the docking to the mutant protein, provided a possible explanation for the
decreased reaction rates of the pregnenolone hydroxylation. Specifically, these structures (Figure 7b,d,f)
hinted at an electrostatic interaction between the methionine methyl group (positively polarized by
the preceding sulfur atom) and the negatively-charged carboxylate found in all ligands we studied.
We propose that this added interaction slows down ligand dissociation/exit and thus slows down
the reaction. Our MD simulation and docking results agree with greatly reduced Vmax but only
marginally increased Km of both the wild-type and V366M mutant of CYP17A1 for the PROG (Table 3),
indicating that binding of PREG and PROG is not affected but the exit of the 17α-hydroxy steroid from
the active site may be slower in the V366M variant.
2.6. Substrate- and Inhibitor-Binding Analysis
Abiraterone bound to the WT CYP17A1 with a Kd value of 95 nM and showed the typical soret
peak at 427 nm, indicative of nitrogen co-ordination with heme iron (Table 5). However, in case of the
V366M mutant of CYP17A1, this binding pattern was not observed. To test the integrity of the protein,
we used imidazole to check the binding and found that imidazole itself could bind to the V366M
mutant. This confirmed our hypothesis that the introduction of the bulky methionine to replace the
valine at position 366 creates steric hindrance and perturbs the binding pattern of drugs and steroids.
These results also point to structural considerations for future inhibitor development which may utilize
the spatial arrangement of binding-site residues to design tight-fitting inhibitors. Progesterone bound
with slightly decreased affinity to the V366M mutant (Kd 287 nM compared to 162 nM for the WT
enzyme). Binding of 17OH-PREG was not observed for the V366M mutation and explained the lack of
17,20 lyase activity, while for the WT CYP17A1 a Kd value 142 nM was observed. It is possible that
some apparent binding of 17OH-PREG may occur at exceedingly high, non-physiological levels due
to the nature of the structural hindrance from the V366M mutation which is at the very end of the
binding site and close to the heme iron and water molecules that occupy the binding pocket.
Since the spectral binding of steroid substrates to CYP17A1 is observed by the replacement of
water molecules at the active site, it is possible for some apparent binding to emerge from titration
studies using very high enzyme and substrate concentrations, but due to unfavorable binding poses
and distances, as revealed by further computational structure analysis, such apparent binding is not
likely to result in an enzyme-substrate complex that can lead to product (DHEA) formation. This is
further evidenced by lack of inhibition by 17OH-PREG in the 17hydroxylation reaction using PROG as
substrate. In the case of inhibitor abiraterone, which needs to form an iron-nitrogen co-ordination and
gets much closer to heme iron than steroid substrates (2.9 Å compared to 4.4–4.8 Å) (Figures 8 and S1),
no binding was observed. Taken together these data indicate a steric hindrance for the binding of
17OH-PREG which may result in poor interaction with the enzyme and loss of 17,20 lyase activity.
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Figure 7. Struct re analysis of the V36 M m t . (a) Binding of preg enolo e in CYP17A1 active
site. Pregnenolone binds perpendicular to he e and is converted to 17OH-PREG. (b) Binding of
pregnenolone to V366M variant of CYP17A1. Pregnenolone can still bind to V366M variant and is
metabolized to 17OH-PREG. The side chain of methionine 366 in the mutant structure protrudes into
the active site but still allows 17OH-PREG to exit. This is likely to slow down the reaction velocity
of the 17α-hydroxylase reaction, which was confirmed by enzyme kinetic experiments (Table 1).
(c) Binding of 17OH-PREG to WT CYP17A1. (d) Docking of 17OH-PREG to V366M variant of CYP17A1.
The 17OH-PREG could not bind in the proximity to heme and distances between the heme iron and C17
atom increased for the mutant enzyme (6.3 Å in the mutant vs. 4.4 Å for the WT enzyme). Increased
iron-C17 distances are observe together with N202-O3 interactions which are considered undesirable
for optimal binding of 17hydroxy steroids for 17,20 lyase reaction. The methion ne 366 side chain in
the mutant protein blocks the entry of 17α-hydroxy steroid into the active site, resulting in loss of 17,20
lyase activity. (e,f) Comparison of WT and V366M variant of CYP17A1 binding to PROG.
Pharmaceuticals 2018, 11, 37 14 of 24
Pharmaceuticals 2018, 11, x FOR PEER REVIEW  14 of 24 
 
 
Figure 8. Comparison of abiraterone interaction with the WT and V366M variant of CYP17A1. (a) In 
the WT CYP17A1 abiraterone binds by forming a nitrogen-iron co-ordination (2.9 Å) with the central 
heme. (b–d) Different poses of abiraterone seen during docking into the V366M mutant of CYP17A1. 
In the V366M mutant, the methionine side chain prevents the binding of abiraterone and increased 
distances between the C17 atom and heme iron are observed together with binding poses that are 
different from the WT. 
Since the spectral binding of steroid substrates to CYP17A1 is observed by the replacement of 
water molecules at the active site, it is possible for some apparent binding to emerge from titration 
studies using very high enzyme and substrate concentrations, but due to unfavorable binding poses 
and distances, as revealed by further computational structure analysis, such apparent binding is not 
likely to result in an enzyme-substrate complex that can lead to product (DHEA) formation. This is 
further evidenced by lack of inhibition by 17OH-PREG in the 17hydroxylation reaction using PROG 
as substrate. In the case of inhibitor abiraterone, which needs to form an iron-nitrogen co-ordination 
and gets much closer to heme iron than steroid substrates (2.9 Å compared to 4.4–4.8 Å) (Figures 8 
Figure 8. Comparison f abiraterone interaction with the WT and V366 f P17A1. (a) In the
WT CYP17A1 abiraterone binds y forming a nitrogen-iro c -ordination (2.9 Å) with the central heme.
(b–d) Different poses of abiraterone seen during docking into the V366M mutant of CYP17A1. In the
V366M mutant, the methionine side chain prevents the binding of abiraterone and increased distances
between the C17 atom and heme iron are observed together with binding poses that are different from
the WT.
2.7. Mechanism of Steroid/Abiraterone Binding and Action in Relation to the V366M Mutation
Docking was performed with all ligands to WT as well as the V366M mutant of CYP17A1. Thr306
is reported to be a vital residue for the hydroxylation reaction (part of an alcohol pair donating protons).
It is also very close to the heme and, like residue 366, is near the bound ligands. Asn202 is reported to
interact with the distal side of the molecules. It is at the end of the cavity formed around the bound
steroids/abiraterone (Figure 6) and most likely one of the residues inside the access channel. Ensemble
docking of all relevant ligands implies that docking poses mimic the co-crystallized abiraterone
(CH3 groups to the left when looking from the direction of residue 366) and allow interaction with the
residue 202 highlighted in recent structures of human CYP17A1 (Figures 8 and 9) [23].
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The pose from which 17α-hydroxy steroid leaves the site (after being formed) may differ from
the one it assumes upon coming back. There are also possible differences between 17OH-PREG and
PROG/PREG binding (Figures 7 and 9). Angular analysis of apo and relaxation V366M simulations
imply that the methionine moves around a single conformation (chi2 and 3 angles roughly in 20-degree
windows—a good match to the rotamers reported by http://www.dynameomics.org). It seems
most likely that the CH3 group is involved in steric effects. The sulfur group in methionine may
further polarize it, enhancing interaction with the carboxylate of 17α-hydroxy steroids. In some MD
poses the methionine could be seen moving away from the heme, indicating it has conformational
flexibility and in the presence of the metabolized PREG/PROG the 17α-hydroxylated ligand may exit
without excessive hindrance. The reduced velocity of the PROG to 17OH-PROG reaction indicates
that there could be an interaction between the carboxylate and the (likely-polarized) CH3 group of
the methionine, which may slow down the exit of the product. Some other differences in the binding
pattern were observed, like the involvement of Arg239 in the interaction of PROG with the V366M
variant which may create bottlenecks during the exit of the product. Computationally calculated
binding constants and binding energy calculations also supported the experimental results of reduced
binding affinities for 17OH-PREG and abiraterone for the V366M mutant (Table 6). All this implies a
general steric hindrance by the bigger residue (methionine vs. valine).
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Table 6. Computational binding energy, computationally calculated dissociation constants, and
interacting residues for steroid substrates and abiraterone with WT and the V366M mutant of CYP17A1.
Key residues identified in different studies are shown in bold.
CYP17A1 Protein Binding Energy(kcal/mol)
Dissociation
Constant (nM) Contacting Residues
WT with Prog 10.6 14.66
ALA113 PHE114 ASN202 ILE205 ILE206 LEU209
ARG239 GLY297 ASP298 GLY301 ALA302
THR306 ALA367 ILE371 VAL482 VAL483 HEME
M366 with Prog 9.75 43.71
ALA113 PHE114 ASN202 ILE205 ILE206 LEU209
ARG239 GLY297 ASP298 GLY301 ALA302
THR306 MET366 ALA367 ILE371 VAL482
VAL483 HEME
WT with Preg 10.7 13.29
ALA105 ALA113 PHE114 ILE205 ILE206 LEU209
VAL236 ARG239 GLY297 ASP298 GLY301
ALA302 GLU305 THR306 VAL366 ILE371
VAL482 VAL483 HEME
M366 with Preg 10.3 27.11
ALA105 SER106 ALA113 PHE114 ILE205 ILE206
LEU209 VAL236 ARG239 GLY297 ASP298
GLY301 ALA302 THR306 MET366 ILE371
VAL482 VAL483 HEME
WT with
17OH-Preg 11.3 5.22
ALA113 PHE114 TYR201 ASN202 ILE205 ILE206
LEU209 LEU214 ARG239 GLY297 ASP298
GLY301 ALA302 THR306 VAL366 ALA367
ILE371 VAL482 VAL483 HEME
M366 with
17OH-Preg 7.0 60.4
ALA113 PHE114 TYR201 ASN202 ILE205 ILE206
LEU209 ARG239 GLY297 ASP298 GLY301
ALA302 GLU305 THR306 MET366 ALA367
ILE371 VAL482 VAL483
WT with
Abiraterone 12.5 0.69
ALA113 PHE114 TYR201 ASN202 ILE205 ILE206
LEU209 ARG239 GLY297 ASP298 GLY301
ALA302 GLU305 THR306 VAL366 ALA367
LEU370 ILE371 VAL482 VAL483 HEME
V366 with
Abiraterone 8.1 1112.9
ALA105 SER106 ASN107 ALA113 PHE114
TYR201 ILE205 ILE206 LEU209 ARG239 THR294
GLY297 ASP298 GLY301 ALA302 THR306
MET366 ILE371 VAL482 VAL483
Given the information from crystal structure of human CYP17A1 with abiraterone (nitrogen
at 2.9 Å from the heme iron) (Figure 8), this implies that PREG either does not have to get this
close to the heme or can accesses it from a different angle and is hence relatively unimpaired by the
methionine. Recent structures of the human CYP17A1 bound with different steroid substrates confirm
this hypothesis and show that 17OH-PREG binds much closer to the heme iron than PROG or PREG
(Figures 7 and 9) [23,24]. For the 17OH-PREG we observed the existence of poses with the hydroxyl
positioned very close to the CH3 of the methionine, indicating the bulky methionine residue could be
preventing the ligand from getting close enough to the heme (Figures 7d and S2).
In addition, we also observed shorter distances suitable for hydrogen bonds with N202 and R239
groups and 17OH-PREG in the docking poses of V366M mutant (2.6 Å compared to 4.4 Å for the WT)
(Figures 7d and S2, Table 6); it has been proposed that these interactions are required for PROG/PREG
but are considered suboptimal for 17,20 lyase reaction and are found together with increased distances
of C17 in 17α-hydroxy steroid substrate and the heme iron. Increased distances between the C17 of
17OH-PREG/Abiraterone and the heme iron, together with the extra/undesired interactions with
N202/R239, were consistently observed in our simulations (Figures 7c, 8 S1 and S2).
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It is more likely that the ligands cannot get into the binding site rather than have too much
difficulty in leaving it since that would block the active site and prevent the 17α-hydroxylation
reaction from occurring (which is not severely affected as observed by enzymatic analysis as well
as the urine steroid profile of the patient). Also, DHEA is the smallest of all steroids involved,
making it the most likely to leave, so it is the entry of 17OH-PREG into the active site that is likely
to be impaired. Many different poses of abiraterone and 17OH-PREG were observed for the V366M
mutant which illustrates the non-optimal binding pattern for the mutant enzyme (Figures 8 and S2).
The inhibitor abiraterone (similar scaffold but bigger than the steroid substrates) also has trouble
binding (Figures 8 and S1, Table 5) and does not act as an inhibitor for the 17α-hydroxylation reaction
catalyzed by the V366M mutant of CYP17A1 (Table 5).
3. Discussion
Among the previously reported mutations causing isolated 17,20 lyase deficiency, the R347C,
R347H and R358Q are located on the redox partner binding site (Figure 6) and seem to act by
altering the interaction with POR. Generally, a defect in redox partner or loss of interaction with
redox partner affects all cytochrome P450 activities in the endoplasmic reticulum as well as in
mitochondria [31,36,44–48]. In the case of R347H and R358Q mutations in CYP17A1, why this loss of
interaction with POR affects the 17,20 lyase activity in a more severe fashion than the 17α-hydroxylase
activity is not clear, since both activities of CYP17A1 require electrons supplied by NADPH through
POR for their catalytic function [49]. The only other mutation in CYP17A1 that had been reported
to selectively impair the 17,20 lyase activity is E305G which is part of the substrate access channel of
CYP17A1 (Figures 6 and 8) [28,30]. The E305G mutation had been reported to affect the binding of
17α-hydroxy steroids while showing even higher than normal 17α-hydroxylase activities [28]; however
a later analysis of the patient’s steroid metabolic profile [30] showed that 17α-hydroxylase activity was
also impaired, contradicting the earlier claims of isolated 17,20 lyase deficiency [30]. A more efficient
coupling with POR and efficient use of NADPH have recently been proposed to favor the 17,20 lyase
reaction [49]. Multiple potential mechanisms for the selectivity of the 17,20 lyase reaction have been
proposed in recent works from different laboratories [23,26,49–53].
The V366M is an active site mutation in CYP17A1 that not only preferentially targets 17,20 lyase
activity but also provides insights into the structural basis of the 17,20 lyase reaction, the key regulator
of sex steroid biosynthesis in humans (Figures 2 and 7). The specificity of the human CYP17A1 active
site allows the binding of PREG and its 17hydroxy metabolite (17OH-PREG) to bind in different
conformations and exit the active site after the reactions (Figure 7a,c), and the mutation of valine
366 to methionine alters the active site and hinders the binding of 17α-hydroxy-steroids (Figure 8d).
The V366M mutant also explains the effectiveness of the anti-prostate-cancer drug abiraterone as a
potent inhibitor of CYP17A1. Abiraterone fills the active site of CYP17A1 (Figures 8 and S1) and
becomes irreversibly bound to the enzyme (Supplementary Figure S1c), stopping any further substrate
binding and activity [22]. This location of V366 at the catalytic center provides a structural basis for
improving and designing novel and specific CYP17A1 inhibitors by targeting spatial selectivity of the
active site with imidazole or other suitable chemical moieties added to core steroid structures.
Structural modifications based on the above information may help in designing more specific
and potent inhibitors directed only towards the 17,20 lyase activity of CYP17A1 that could produce
tighter binding at the active site. The 17,20 lyase-specific inhibitors will have advantages over current
compounds that target both the 17α-hydroxylase and the 17,20 lyase activities of CYP17A1 and require
steroid supplementation [12,54–58]. The mechanistic and structural insights revealed by these studies
will help in the development of better drugs against polycystic ovary syndrome and prostate cancer.
These findings will also improve our understanding of the structural basis of the dual function of
CYP17A1 as both a 17α-hydroxylase and 17,20 lyase, and the role of these activities in the regulation
of steroid hormone production in different tissues.
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4. Materials and Methods
4.1. Human Subjects
All clinical investigations were carried out following the Declaration of Helsinki principles.
Written informed consent was received from the parents for genetic work-up of 46, XY DSD in their
child in the pediatric endocrinology research laboratory in Barcelona which holds ethical approval for
these studies.
4.2. Genetic Analysis
DNA was extracted from the peripheral blood leucocytes of the patient. Genetic analysis of
the androgen receptor gene (AR) and for the 5αreductase type 2 gene (SRD5A2) were performed as
described [39,40], yielding normal results. The CYP17A1 gene was analyzed as reported [59] and
identified sequence variations were compared to National Center for Biotechnology Information
(NCBI, Bethesda, USA) entry NG_007955.1 (GI:189339218). The CYP17A1 gene was subsequently also
analyzed in the parents and the older half-sister, and one mutation was found in the mother. Since the
second mutation is a completely inactivating mutation, its presence on a different allele was inferred
(as the presence of both mutations on one allele will give a good working copy of the CYP17A1 gene,
and that does not cause disease).
4.3. Steroid Profiling from 24-h Urine Samples
Steroid metabolites in urine were measured by the gas chromatography-mass spectrometry
(GC/MS) method as described previously [60,61].
4.4. Recombinant Protein Expression
Human wild-type and mutant CYP17A1 proteins were produced in an E. coli expression system
and purified for enzyme kinetic assays [15,17,18,62]. The pCWH17-mod(His)4 expression plasmid
(a gift from Prof. Michael Waterman, Nashville, TN) containing the cDNA for human WT or mutant
CYP17A1 [15], was transformed into the E. coli JM109 cells and colonies were selected under ampicillin
control. Bacteria were grown at 37 ◦C to OD600 0.6 and the CYP17A1 protein expression was induced
by the addition of 0.5 mM IPTG followed by further incubation at 28 ◦C for 48 h. Purification of
CYP17A1 was performed as described [15,17,18]. In brief, the spheroplasts prepared by the lysozyme
treatment of bacterial cells were ruptured by sonication and cleared by centrifugation at 4000× g
for 10 min, then the supernatant containing the CYP17A1 protein was extracted with 1.5% Triton
X-114 and centrifuged at 100,000× g for 30 min. A reddish-brown colored detergent-rich supernatant
fraction containing the CYP17A1 was isolated, diluted to reduce the detergent concentration to 0.1%,
and passed over a Ni-NTA-sepharose column. The column was washed with 5 mM histidine to remove
the non-specific binding and eluted with 200 mM histidine. Further purification was carried out by gel
filtration chromatography to remove histidine and other protein contaminants.
4.5. In Vitro Enzyme Kinetic Analysis of Identified CYP17A1 Mutations
To assess 17α-hydroxylase activity, 10 pmol of CYP17A1 along with 20 pmol purified human
POR [17,31,32,34,62] (at a 1:2 ratio) was incubated with 0.1–15 µM [14C]PROG (80,000 cpm/reaction)
and 1 mM NADPH in 50 mM potassium-phosphate buffer (pH 7.4) containing 6 mM potassium
acetate, 10 mM MgCl2, 1 mM reduced glutathione, 20% glycerol and 20 µg phosphatidylcholine for
60 min at 37 ◦C. Human CYP17A1 does not use 17OH-PROG as a major substrate and, therefore,
PROG is considered a better substrate to monitor only 17α-hydroxylase activity due to very little
further conversion of 17OH-PROG. To assess 17,20 lyase activity, CYP17A1 and POR proteins were
incubated with 0.05–5 µM [3H]17OH-PREG (100,000 cpm/reaction), 1 mM NADPH and 20 pmol
cytochrome b5/reaction in 50 mM K-phosphate buffer (pH 7.4) containing 6 mM potassium acetate,
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10 mM MgCl2, 1 mM reduced glutathione, 20% glycerol and 20 µg phosphatidylcholine for 90 min
at 37 ◦C. Steroids were extracted and resolved by thin layer chromatography before quantitative
analysis for conversion to 17OH-PREG and DHEA respectively as described [19]. For inhibition
assays, abiraterone, PREG as well as 17OH-PREG were used to compete with radioactive PROG for
17α-hydroxylase reaction. Enzyme kinetic calculations were performed using non-linear regression
curve fitting with Prism (GraphPad Software Inc., San Diego, CA, USA). Data represent the mean of
three independent experiments.
4.6. Heme and P450 Measurements
Heme content was measured as described previously by dissolving the protein in NaOH and
measuring the heme absorbance in a triton-methanol mixture [63]. Cytochrome P450 and Cytochrome
b5 were measured as described previously [1,17]. Cytochrome b5 content was estimated by monitoring
the absorbance difference at 423–490 nm using an extinction coefficient of 181 mmol cm−1.
4.7. Substrate-Binding Assay
Binding of steroid substrates to CYP17A1 was measured by recording the substrate-binding
spectra in the range of 340–500 nm on a Perkin Elmer Lambda 25 spectrophotometer. A change in heme
absorbance is observed when water molecules at the active site are replaced by steroid substrates [22].
In case of abiraterone, an increase in the soret peak at 427 nm is observed by co-ordination of the
heme iron with pyridine nitrogen. To accurately measure the tight binding substrates and inhibitors,
a cuvette with 100 mm path length was employed and protein concentration was kept at 50 nM.
Binding of steroids, as well as abiraterone to CYP17A1, occurs with very high affinity and, as observed
previously, Kd values measured are often close to protein concentration used in binding assays.
All substrates and abiraterone were dissolved in ethanol and an equal amount of ethanol was added to
the reference cuvette and the final concentration of ethanol added to the cuvettes was kept below 2%.
After each addition of the compounds, cuvettes were incubated for 5 min at 22 ◦C before recording
the spectra. The slit width was fixed at 1.0 nm and spectra were recorded at 50 nm/min with a
series of increasing concentrations of different compounds (abiraterone: 0–200 nM; PREG: 0–500 nM;
17OH-PREG: 0–1000 nM; PROG: 0–1000 nM). Data were fitted with GraphPad Prism based on the
tight binding pattern of substrates to a single binding site.
4.8. Protein Structure Analysis of WT and Mutant CYP17A1
The published 3D structures of human CYP17A1 [22,23] were downloaded from the protein
structure repository (www.rcsb.org). We performed several rounds of multiple-sequence alignments
with different CYP17A1 protein sequences from several organisms and created in-silico mutants
using the programs YASARA [64] and WHATIF [65]. For all further experiments described, a 2.6 Å
resolution crystal structure [22] (PDB code 3RUK) of CYP17A1 was used; with the abiraterone ligand,
the membrane anchor (all residues preceding R45), and water molecules (aside from one conserved
between residue 366 and the heme) removed. Missing hydrogen atoms were added to the structure
with YASARA [64] which was also used for all other computations. The V366M mutant model was then
constructed by replacing the original valine with the most favorable methionine conformation found
with the in-built SCWALL method (rotamer library search followed by energy minimization) [66].
Afterward, both systems were subjected to 10 ns explicit solvent MD simulations at 310 K, which was
preceded by 500 steps of steepest descent and simulated annealing minimization using the AMBER03
force field and the TIP3P water model [67,68]. All following MDs were performed with similar settings.
The resulting simulation snapshots (100 per run) were used for the docking of steroids with the
AutoDock Vina [69] ensemble-docking experiments using PREG, 17OH-PREG, PROG and 17OH-PROG
(orthorhombic docking was grid-established around the central heme and the residues 105, 202, and 366
of the CYP17A1). The final selection of poses was based on their docking scores and similarities to the
abiraterone ligand which was co-crystallized in the template structure (PDB: 3RUK) [22]. The docked
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steroid poses agreed with the binding site details highlighted by a recent set of CYP17A1 crystal
structures [23]. Clustering of simulation snapshots was done using USCF Chimera [70]. Figures of the
structure models were created with the program Pymol (www.pymol.org) and the chosen poses were
rendered as ray-traced images with POVRAY (www.povray.org). Ligand interactions were analyzed
and depicted with the program LIGPLOT+ (http://www.ebi.ac.uk/thornton-srv/software/LigPlus/).
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/11/2/37/s1,
Supplementary Figures S1 and S2.
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